CA
NZ
UK
AU
IND
US
Prestige Consumer Healthcare Inc. (NYSE: PBH) is set to experience a significant leadership shift with the upcoming retirement of Jeffrey Zerillo, who currently serves as Senior Vice President of Operations. His retirement is officially effective on August 14, 2026, as he informed the company …
LeonaBio, Inc. (NASDAQ: LONA) posted a net loss of $19.0 million for the quarter ending June 30, 2026, reflecting the financial impact of a strategic shift toward intensive research and development activity. The escalation in losses is directly tied to the company’s ramp‑up of …
Lifeward posted Q2 2026 revenue of $6.6 million, a 16% increase from the prior year, while cash rose to roughly $11 million after a $5.6 millionCapitalinfusion. The strongerTop Lineand expandedLiquiditygive investors confidence in the company’s execution and funding runway.
Mesoblast announced the conclusion of its Phase 3 trial targeting low back pain, a study that enrolled 350 participants. The news sparked a 9% jump in the company’s share price, a reaction that rippled through the Australian biotech segment and highlighted the market’s appetite …
The licensing arrangement delivered both an upfront cash injection and a stream of ongoingRoyaltypayments, which the company booked as revenue during the reporting quarter. Those royalty receipts, together with the cash payment, comprised the majority of the $6.3 million revenue total reported for the …
Enveric Biosciences (NASDAQ: ENVB) announced a second‑quarter net loss of $3.0 million, equating to a diluted loss per share of $0.76, while simultaneously generating $5.0 million of upfront gross proceeds from a private placement and an extra $1.5 million from exercised warrants. Cash on …
Femasys Inc. secured $30 million through a private placement, providing the cash needed to fund its U.S. commercial strategy and move its FemBloc clinical program forward. The infusion improves liquidity, restoresNasdaqcompliance and gives investors a stronger financial foundation for upcoming growth initiatives.
The financial performance of HCW Biologics Inc. (NASDAQ: HCWB) in the second quarter showcased substantial progress, with revenues reaching $135,568, marking a dramatic increase from $6,550 reported in the corresponding quarter of the previous year. This impressive surge is a direct reflection of the …
HeartBeam, Inc. has entered into a significant At-The-Market Equity Offering Sales Agreement, enabling the company to sell an aggregate of up to $25 million of its common stock. This arrangement comes through an agreement signed with Titan Partners Securities LLC as the sales agent. …
Heron Therapeutics, Inc. (NASDAQ: HRTX) has taken a significant step by extending its Tax Benefit Preservation Plan's expiration date to August 14, 2029. This amendment modifies the prior expiration date, initially set for August 14, 2026. By pushing this deadline three more years into …
Please wait processing your request...